The carboxyl terminus of VEGF-A is a potential target for anti-angiogenic therapy

Association between VEGF Splice Isoforms and Progression-Free Survival in Metastatic Colorectal Cancer Patients Treated with Bevacizumab

(2012) D. O. Bates et al.   CLINICAL CANCER RESEARCH

Long-term effect of intravitreal injection of anti-VEGF agent for visual acuity and chorioretinal atrophy progression in myopic choroidal neovascularization

(2012) Akio Oishi et al.   GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY

Structural Basis for Selective Vascular Endothelial Growth Factor-A (VEGF-A) Binding to Neuropilin-1

(2012) Matthew W. Parker et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab

(2011) Paul Mitchell   CURRENT MEDICAL RESEARCH AND OPINION

Effects of exogenous VEGF165b on invasion and migration of human lung adenocarcinoma A549 cells

(2011) Jing Chen et al.   Journal of Huazhong University of Science and Technology-Medical Sciences

Neutralization of Vascular Endothelial Growth Factor Antiangiogenic Isoforms Is More Effective Than Treatment with Proangiogenic Isoforms in Stimulating Vascular Development and Follicle Progression in the Perinatal Rat Ovary1

(2009) Robin A. Artac et al.   BIOLOGY OF REPRODUCTION

Regulation of Vascular Endothelial Growth Factor (VEGF) Splicing from Pro-angiogenic to Anti-angiogenic Isoforms

(2009) Dawid G. Nowak et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

VEGF165b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy

(2008) A H R Varey et al.   BRITISH JOURNAL OF CANCER

The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice

(2008) E S Rennel et al.   BRITISH JOURNAL OF CANCER

Vascular Endothelial Growth Factor (VEGF)-A165b Is a Weak In vitro Agonist for VEGF Receptor-2 Due to Lack of Coreceptor Binding and Deficient Regulation of Kinase Activity

(2008) H. Kawamura et al.   CANCER RESEARCH

Failure to up-regulate VEGF165b in maternal plasma is a first trimester predictive marker for pre-eclampsia

(2008) Victoria L. Bills et al.   CLINICAL SCIENCE

Recombinant human VEGF165b protein is an effective anti-cancer agent in mice

(2008) Emma S. Rennel et al.   EUROPEAN JOURNAL OF CANCER

Mammary alveolar development during lactation is inhibited by the endogenous antiangiogenic growth factor isoform, VEGF165b

(2007) Yan Qiu et al.   FASEB JOURNAL